Skip to main content

Table 1 Demographic and treatment characteristics of study cohort (N = 41)

From: Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose–response relationship of parotid-sparing radiotherapy in head-neck cancers

Characteristics

Number

Age:

 

Median

54 years

Range

33-65 years

Gender:

 

Male

37 (90.2%)

Female

04 (09.8%)

Primary site:

 

Oropharynx

23 (56.1%)

Larynx

10 (24.4%)

Hypopharynx

08 (19.5%)

Laterality (epicentre):

 

Right

22 (53.7%)

Left

18 (43.9%)

Midline

01 (02.4%)

American Joint Committee on Cancer (AJCC) staging:

 

Stage II

09 (21.9%)

Stage III

17 (41.5%)

Stage IV

15 (36.6%)

Radiotherapy technique:

 

Three-Dimensional Conformal Radiotherapy (3D-CRT)

20 (48.8%)

Intensity-Modulated Radiation Therapy (IMRT)

21 (51.2%)

Median (inter-quartile range) of mean parotid dose:

 

Ipsilateral parotid

50.0 Gy (36.2-59.7)

Contralateral parotid

35.4 Gy (28.0-53.5)

Concurrent chemotherapy:

 

Yes

38 (92.6%)

No

03 (07.4%)